Lansoprazolo Sun Pharma Italia Srl

Lansoprazole, the active ingredient in Lansoprazolo Sun Pharma Italia Srl, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens and Zollinger‑Ellison syndrome in adult patients. GNH USA supplies Lansoprazolo Sun Pharma Italia Srl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to lower gastric acidity in several acid‑related disorders.

Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a less acidic gastric environment. Helicobacter pylori eradication: used in combination therapy to increase eradication rates by suppressing acid that protects the bacteria. Zollinger‑Ellison syndrome: controls excessive gastric acid secretion caused by gastrin‑producing tumors.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Severe allergic reactions: including anaphylaxis, Stevens‑Johnson syndrome. - Clostridioides difficile infection: risk of severe colitis. - Low serum magnesium: may cause muscle cramps, arrhythmias. - Bone fractures: increased risk with long‑term use. - Interstitial nephritis: inflammation of kidney tissue.

Before prescribing lansoprazole, clinicians should consider several safety aspects.

Assess renal function: dose adjustment may be needed in severe impairment. Monitor magnesium levels: especially during prolonged therapy. Use caution in elderly patients: higher incidence of fractures and infections. Avoid concomitant use with drugs requiring acidic environment for absorption. Review pregnancy and lactation status: safety data are limited. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clarithromycin: increased risk of arrhythmias and elevated drug levels. - Ketoconazole: reduced absorption due to decreased gastric acidity. - Atazanavir: markedly reduced plasma concentrations, compromising HIV therapy.

Moderate Interactions (Monitor Closely): - Digoxin: higher serum concentrations may occur. - Methotrexate: reduced clearance can lead to toxicity. - Phenytoin: decreased effectiveness due to altered metabolism.